Baird Downgrades Sarepta Therapeutics (SRPT) to Neutral, 'Transparency Issues and Elevidys Uncertainty'
Tweet Send to a Friend
(Updated - July 18, 2025 2:19 PM EDT)
Baird analyst Brian Skorney downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst Brian Skorney downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
